The Australian market has never een skilled at valuing emerging...

The Australian market has never een skilled at valuing emerging "bio-pharmo" emerging talent.
Here is a company packed to the ceilings with some of the best researchers in the world ( who are also Australians) and engaged in stage two trials here and with with a leading Canadian centre. This has the potential to be worth a fortune and it looks as if the work and the profits will end up with a foreign company...sometimes we are so dumb!!!
An extract from Haselhurst's article which is really just drawing on Company info

"The technology uses naturally occurring viruses to identify, invade and destroy malignant cells. Earlier work led by associate professor of virology Darren Shafren (now also a non-executive director of Viralytics) demonstrated promising results on cancer-afflicted mice. Those injected with the virus showed that cancer cells would break apart six to 10 hours after infection, releasing thousands more replicated viruses into the tumour. Treatments on mice at all dosage strengths reduced tumour growth over 35 days, and at higher dosages they were eliminated.

Encouraging first-stage trials have been conducted on humans to test toxic tolerance levels. In September, approval was granted for stage-two trials with melanoma sufferers. It was then signalled that enrolments would begin "shortly" for second-phase trials on late-stage breast and prostate cancer. Trials are also under way on brain tumours with the Labatt research centre in Toronto, Canada".